Q2 FY2026 · ended Jun 30, 2026 · Revenue $1.51M, +19.0% YoY · Filed Aug 7, 2026
bioAffinity Technologies, Inc. (BIAF) files with the SEC under industry code 8731, Services-Commercial Physical & Biological Research. In Q2 of fiscal 2026, the quarter ended Jun 30, 2026, it reported revenue of $1.5 million and a net loss of $3.4 million. Free cash flow was -$3.3 million. As of Jun 30, 2026 it held $2.4 million in cash and investments and $1.4 million in total debt.
Company profile
- Industry
- Services-Commercial Physical & Biological Research (SIC 8731)
- Listed as
- BIAF (Nasdaq), BIAFW (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- San Antonio, TX
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1712762
- Former names
- bioAffinity Technologies, Inc. (until Nov 3, 2026)
Other Services-Commercial Physical & Biological Research companies
- Iqvia Holdings Inc. IQV
- Incyte Corp INCY
- Medpace Holdings, Inc. MEDP
- Charles River Laboratories International, Inc. CRL
- Icon PLC ICLR
- Absci Corp ABSI
- OmniAb, Inc. OABI
- NRC Health NRC
All 17 Services-Commercial Physical & Biological Research companies
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $1.5M | $1.4M | $1.6M | $1.4M | $1.3M |
| Operating income | -$3.3M | -$3.6M | -$3.1M | -$2.3M | -$2.5M |
| Net income | -$3.4M | -$3.6M | -$3.1M | -$5.1M | -$4.1M |
| Diluted EPS | -$0.64 | -$0.81 | -$0.71 | -$4.74 | -$5.07 |
| Operating cash flow | -$3.2M | -$3.2M | -$2.6M | -$2.5M | -$2.6M |
| Free cash flow | -$3.3M | -$3.2M | -$2.6M | -$2.5M | -$2.7M |
| Total assets | $7.6M | $7.9M | $11.0M | $11.5M | $4.8M |
| Total liabilities | $3.9M | $4.3M | $3.7M | $2.6M | $6.9M |
| Stockholders' equity | $3.8M | $3.6M | $7.3M | $8.9M | -$2.1M |
| Cash and investments | $2.4M | $3.1M | $6.4M | $7.7M | $802,835 |
| Total debt | $1.4M | $1.3M | $1.0M | $760,894 | $591,099 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Other events
|
Oct 29, 2026 | Oct 29, 2026 |
| 8-K |
Current report
Other events
|
Oct 15, 2026 | Oct 15, 2026 |
| 8-K |
Current report
Other events
|
Oct 13, 2026 | Oct 13, 2026 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Other events
|
Oct 9, 2026 | Oct 8, 2026 |
| 8-K |
Current report
Other events
|
Oct 8, 2026 | Oct 8, 2026 |
| 8-K |
Current report
Other events
|
Oct 6, 2026 | Oct 6, 2026 |
All 399 bioAffinity Technologies, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.